SL PHARM(002038)2022-04-25 16:00Financial Performance - Revenue for Q1 2022 was CNY 274,551,424.02, an increase of 8.59% compared to CNY 252,832,785.33 in the same period last year[6] - Net profit attributable to shareholders decreased by 31.07% to CNY 63,295,907.68 from CNY 91,830,018.08 year-on-year[6] - Net profit excluding non-recurring gains and losses increased by 10.83% to CNY 73,614,401.47 from CNY 66,422,502.97 in the previous year[6] - Basic and diluted earnings per share were both CNY 0.06, a decrease of 33.33% from CNY 0.09 in the previous year[6] - Total operating revenue for the current period reached ¥274,551,424.02, an increase from ¥252,832,785.33 in the previous period, reflecting a growth of approximately 8.5%[39] - Net profit for the current period was ¥62,249,029.27, compared to ¥89,530,588.26 in the previous period, representing a decline of approximately 30.5%[41] - The total comprehensive income for the current period was ¥62,740,867.75, compared to ¥91,312,574.99 in the previous period, representing a decline of approximately 31.3%[45] Cash Flow and Assets - Operating cash flow for the period was CNY 81,984,125.26, up 5.81% from CNY 77,482,058.85 in the same quarter last year[6] - The company's cash and cash equivalents at the end of the first quarter of 2022 amounted to ¥859,910,919.76, an increase from ¥827,837,220.81 at the beginning of the year[29] - The total current assets increased to ¥2,368,782,177.32 from ¥2,297,730,398.98 at the beginning of the year, reflecting a growth of approximately 3.4%[29] - The company's total liabilities decreased to ¥409,030,706.59 from ¥434,234,069.90, a reduction of about 5.8%[38] - The net cash flow from operating activities amounted to 77,482,058.85 in the previous period[48] - The ending balance of cash and cash equivalents was 812,366,498.58[51] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 55,306[20] - The largest shareholder, Xu Mingbo, holds 22.63% of the shares, totaling 232,456,307 shares[20] - The second largest shareholder, Xinxiang Bailu Investment Group Co., Ltd., holds 16.67% of the shares, totaling 171,216,272 shares[20] Investments and Expenses - Research and development expenses for the current period were ¥37,264,321.08, down from ¥45,726,838.61, indicating a decrease of about 18.6%[39] - The company reported investment income of ¥16,917,242.02, a decrease from ¥24,280,027.99 in the previous period, reflecting a decline of approximately 30.1%[42] Other Financial Metrics - Total assets at the end of the reporting period were CNY 5,797,919,333.17, reflecting a 0.65% increase from CNY 5,760,463,945.50 at the end of the previous year[6] - Shareholders' equity attributable to the parent company increased by 1.17% to CNY 5,373,741,301.78 from CNY 5,311,497,706.49 at the end of the previous year[6] - The company's accounts receivable decreased to ¥335,861,538.53 from ¥345,833,195.76, indicating a decline of about 2.8%[29] - The inventory increased to ¥148,198,164.74 from ¥124,831,537.76, representing a growth of approximately 18.7%[29] - The company's long-term equity investments increased slightly to ¥900,698,281.10 from ¥899,466,656.57[31] Impact of External Factors - The decline in net profit was attributed to significant changes in the fair value of other non-current financial assets held by the company[18] - The company anticipates potential impacts on product sales and clinical trials due to ongoing pandemic control measures, which may adversely affect performance[25]